Mallinckrodt, a leading global specialty biopharmaceutical company, has announced a €45 million investment to expand its Dublin-based operations, creating 45 skilled full-time positions. A new state-of-the-art manufacturing facility and office building are to be located at College Business and Technology Park, Blanchardstown, Dublin 15. The development will provide 300 jobs during the two-year construction. Mallinckrodt already employs more than 120 people at its existing manufacturing site and offices in Dublin. The new facility will include a two-storey manufacturing building, a three-storey administration building and additional areas for future investment on a c.4.85 hectare site. “We are proud to have had a significant presence in Ireland for more than two decades, and today marks an important step for the company. Our Irish workforce has served as a tremendous asset to our global operations to date. We are particularly pleased to be making this sizeable capital investment today, continuing our long-standing operations in Ireland,” said Mark Trudeau, chief executive officer and president of Mallinckrodt. The company has invested more than €165million in Ireland over the past 22 years. It provides treatment options for patients with a wide variety of health conditions, with a focus on autoimmune and rare diseases, analgesia, neonatal critical care respiratory therapies, and central nervous system disorders.